Don't Sell Yourself Out

When does an early stage pharmaceutical company trade too much of itself away in exchange for investment? Foley Hoag’s Hemmie Chang and a panel of biopharmaceutical industry experts plumbed that question during a discussion on option deals at the BIO 2012 conference in Boston. Hemmie offered some perspective after the session on what early stage pharmaceutical companies should understand about protecting their IP in option deals – but often don’t.